Final results of dose-finding phase II trial with a triple combination therapy in metastatic renal cell cancer (mRCC): Bevacizumab (B) plus immunotherapy (IT) plus chemotherapy (C) (BIC), antitumor effects, and variations of circulating T-regulatory cells (TREG) / Passalacqua, R; Buti, S; Brighenti, M; Rivoltini, L; Castelli, C; Camisaschi, C; Simonelli, C; Lo Re, G; Mattioli, R; Lazzarelli, S. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 28:15(2010), pp. 336s-336s. [10.1200/jco.2010.28.15_suppl.4615]

Final results of dose-finding phase II trial with a triple combination therapy in metastatic renal cell cancer (mRCC): Bevacizumab (B) plus immunotherapy (IT) plus chemotherapy (C) (BIC), antitumor effects, and variations of circulating T-regulatory cells (TREG)

Buti S;
2010

Final results of dose-finding phase II trial with a triple combination therapy in metastatic renal cell cancer (mRCC): Bevacizumab (B) plus immunotherapy (IT) plus chemotherapy (C) (BIC), antitumor effects, and variations of circulating T-regulatory cells (TREG) / Passalacqua, R; Buti, S; Brighenti, M; Rivoltini, L; Castelli, C; Camisaschi, C; Simonelli, C; Lo Re, G; Mattioli, R; Lazzarelli, S. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 28:15(2010), pp. 336s-336s. [10.1200/jco.2010.28.15_suppl.4615]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2906877
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact